AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 72 min read$JNJ

Forminard Elizabeth sold $4.1M of JNJ

Forminard Elizabeth (EVP, Chief Legal Officer) sold 15,918 shares of JOHNSON & JOHNSON (JNJ) at an average of $257.00 ($255.93–$257.76, $4.09M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Forminard Elizabeth
Published Aug 7, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the company’s EVP and Chief Legal Officer, including trade dates, share count, and total value.

02

Market read

Traders may note insider selling, but the disclosure does not provide new operational or financial guidance for JNJ.

03

What to watch

The filing does not disclose intent, tax context, or whether additional sales occurred around the same period; without that, price reaction should be muted.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after-hours; reflects trades dated 2026-08-06

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Johnson & Johnson disclosed via Form 4 that EVP Chief Legal Officer Forminard Elizabeth sold 15,918 shares for about $4.09M on 2026-08-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by additional disclosures or company-specific news.

Evidence & confidence

Form 4 provides transaction details but does not indicate new corporate guidance, litigation, or operational changes. The sale size is moderate relative to JNJ and lacks a stated catalyst in the filing.

Market effects

Sector

Insider selling in a mega-cap healthcare name is not a reliable sector signal without broader pattern or sector-specific regulatory/earnings catalysts.

Regional

No clear regional spillover; this is company-specific insider transaction disclosure.

Global

Minimal global relevance; JNJ is widely held, but this filing alone does not change global fundamentals.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan could be misread as bearish; executives may sell for diversification or tax reasons unrelated to outlook.

Key entities

  • issuer
    Johnson & Johnson

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Forminard Elizabeth

    EVP, Chief Legal Officer who sold shares via open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

JNJ insider trading history →

Related articles

OCT 15
$JNJMedAI 8/10

Johnson & Johnson outlook: bull and bear cases after Q3 earnings

Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.

investing.com2 min
OCT 14
$JNJMedAI 8/10

Johnson & Johnson CFO taps internal investment for medtech growth

Johnson & Johnson CFO Joseph Wolk stated the company will use internal investments to drive medtech growth, aiming for double-digit growth by 2030. Q3 medtech sales rose 2.5%, below expectations, but innovative medicine sales offset this. J&J reported $25B in net sales, up 6%, but net earnings dropped 96% YoY due to M&A and litigation costs. The company expects $101B-$101.4B in 2026 sales.

finance.yahoo.com2 min
OCT 14
$JNJHigh

Johnson & Johnson PR: Tylenol Recall to Talc Settlement

Johnson & Johnson (J&J) announced a $5.5B talc settlement on July 27, 2026, covering 76,000 ovarian cancer claims. The company expects to pay $3B in 2027, with the total potentially reaching $7B. J&J is also separating its orthopaedics business, DePuy Synthes, with a 2025 sales of $9.3B. Additionally, Kenvue, J&J's consumer health spinoff, was acquired by Kimberly-Clark for $48.7B in 2025. J&J's 2025 sales outlook was $93.5B to $93.9B.

everything-pr.com2 min
OCT 14
$JNJHighAI 8/10

J&J posts weak medical device sales, shares fall

Johnson & Johnson reported medical device sales of $8.6B, missing estimates of $8.71B, citing geopolitical issues. Shares fell 6%. CFO Joe Wolk attributed weakness to Middle East conflict, European austerity, and China pricing. The company raised its full-year sales forecast to $101.2B and adjusted earnings to $11.10 per share. Pharmaceutical sales rose 7.7% to $16.76B, with Tremfya sales up 68% to $2.4B.

manilatimes.net2 min